Global Drug Repurposing Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Drug Repurposing Market size is expected to reach USD 57.73 Billion in 2034 from USD 37.28 Billion (2025) growing at a CAGR of 4.98% during 2026-2034.

The global drug repurposing market is gaining significant momentum as pharmaceutical companies explore new therapeutic uses for existing drugs. Drug repurposing involves identifying new medical applications for already approved or investigational drugs, which helps reduce development costs and timelines. The rising cost of traditional drug discovery and increasing demand for faster treatment solutions are key factors driving the growth of this market.

Advancements in data analytics, artificial intelligence, and bioinformatics are enabling researchers to identify potential drug repurposing opportunities more efficiently. Pharmaceutical companies and research institutions are leveraging large datasets and computational tools to analyze drug interactions and discover new treatment possibilities. This approach has gained attention in areas such as oncology, infectious diseases, and rare diseases.

In the coming years, the drug repurposing market is expected to expand significantly as the pharmaceutical industry seeks cost-effective strategies for drug development. Increasing collaborations between academic institutions, biotech companies, and pharmaceutical firms will accelerate research efforts. Furthermore, the growing focus on personalized medicine and targeted therapies will create new opportunities for drug repurposing initiatives.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Indication

Oncology
CNS Diseases
Neurodegenerative Diseases
Others (Rare Disorders, etc.)

By Approach Type

Disease-centric Approach
Target-centric Approach
Drug-centric Approach

By End User

Hospitals & Clinics
Ambulatory Surgery Centers
Others (Research Institutes, etc.)

COMPANIES PROFILED

Algernon Pharmaceuticals, Biovista Inc, Celentyx Ltd, ChemBio Discovery Inc, Chord Therapeutics SA, Excelra, Fios Genomics Ltd, Lantern Pharma Inc, Novartis AG, Paradigm Biopharmaceuticals Limited, Predictive Oncology, Segue Therapeutics LLC, Teva Pharmaceutical Industries Ltd
We can customise the report as per your requirements.

Product Code: VMR112111557

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL DRUG REPURPOSING MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Disease Indication
4.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. CNS Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Others (Rare Disorders, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DRUG REPURPOSING MARKET: BY APPROACH TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Approach Type
5.2. Disease-centric Approach Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Target-centric Approach Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Drug-centric Approach Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DRUG REPURPOSING MARKET: BY END USER 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End User
6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Ambulatory Surgery Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Others (Research Institutes, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DRUG REPURPOSING MARKET: BY REGION 2022-2034 (USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Disease Indication
- 7.2.2 By Approach Type
- 7.2.3 By End User
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Disease Indication
- 7.3.2 By Approach Type
- 7.3.3 By End User
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Disease Indication
- 7.4.2 By Approach Type
- 7.4.3 By End User
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Disease Indication
- 7.5.2 By Approach Type
- 7.5.3 By End User
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Disease Indication
- 7.6.2 By Approach Type
- 7.6.3 By End User
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DRUG REPURPOSING INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Algernon Pharmaceuticals
- 9.2.2 Biovista Inc
- 9.2.3 Celentyx Ltd
- 9.2.4 ChemBio Discovery Inc
- 9.2.5 Chord Therapeutics SA
- 9.2.6 Excelra
- 9.2.7 Fios Genomics Ltd
- 9.2.8 Lantern Pharma Inc
- 9.2.9 Novartis AG
- 9.2.10 Paradigm Biopharmaceuticals Limited
- 9.2.11 Predictive Oncology
- 9.2.12 Segue Therapeutics LLC
- 9.2.13 Teva Pharmaceutical Industries Ltd